We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PRA Health Unit to Offer Free Access to Metys COVID-19 Module
Read MoreHide Full Article
PRA Health Sciences, Inc. recently announced that Symphony Health, a PRA Health Sciences subsidiary, will make a 30-day license of its newly-launched Metys COVID-19 Module. It is currently available to the U.S. life science industry free of cost.
This development is likely to boost PRA Health’s Data Solutions segment, which offers data, analytics, technology, and consulting solutions to the life sciences market.
More About the Module
The COVID-19 Module within the Metys platform will offer up to three users per company access to all drugs and markets within any U.S. geographic region down to CBSA (core-based statistical area).
Powered by Symphony’s IDV (Integrated Dataverse), Metys is a unique platform that delivers fast and comprehensive pharmaceutical market analytics. Metysis a web-based tool that accurately integrates prescription, payer, and anonymized patient data through one single access point. It delivers insights swifter than any other tool in the market. Metys has access to over 60 terabytes of automatically included weekly and monthly data.
The global COVID-19 pandemic has thrown an unprecedented challenge to the life sciences industry in the United States and across the globe. Experts in the field of life sciences can use the data and insights available through this platform to observe trends and take action accordingly.
Recent Development
In March, PRA Health announced the expansion of its market-leading Mobile Health Platform, which has been designed to facilitate remote clinical monitoring. This has been done by adding several new capabilities that cater to sponsor needs for COVID-19 virtual study support.
Market Prospects
Per a report byMarketWatch.com, the life science analytics market is projected to see a CAGR of 11.91% during the 2019 to 2025 period. It valued $19.16 billion in 2018.
Price Performance
In the past year, the company’s shares have outperformed the industry.The stock has lost 11.8% compared with the industry’s 27.5% decline.
DexCom’s long-term earnings growth rate is estimated at 36.7%. The company presently carries a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is estimated at 10%. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
PRA Health Unit to Offer Free Access to Metys COVID-19 Module
PRA Health Sciences, Inc. recently announced that Symphony Health, a PRA Health Sciences subsidiary, will make a 30-day license of its newly-launched Metys COVID-19 Module. It is currently available to the U.S. life science industry free of cost.
This development is likely to boost PRA Health’s Data Solutions segment, which offers data, analytics, technology, and consulting solutions to the life sciences market.
More About the Module
The COVID-19 Module within the Metys platform will offer up to three users per company access to all drugs and markets within any U.S. geographic region down to CBSA (core-based statistical area).
Powered by Symphony’s IDV (Integrated Dataverse), Metys is a unique platform that delivers fast and comprehensive pharmaceutical market analytics. Metysis a web-based tool that accurately integrates prescription, payer, and anonymized patient data through one single access point. It delivers insights swifter than any other tool in the market. Metys has access to over 60 terabytes of automatically included weekly and monthly data.
The global COVID-19 pandemic has thrown an unprecedented challenge to the life sciences industry in the United States and across the globe. Experts in the field of life sciences can use the data and insights available through this platform to observe trends and take action accordingly.
Recent Development
In March, PRA Health announced the expansion of its market-leading Mobile Health Platform, which has been designed to facilitate remote clinical monitoring. This has been done by adding several new capabilities that cater to sponsor needs for COVID-19 virtual study support.
Market Prospects
Per a report by MarketWatch.com, the life science analytics market is projected to see a CAGR of 11.91% during the 2019 to 2025 period. It valued $19.16 billion in 2018.
Price Performance
In the past year, the company’s shares have outperformed the industry.The stock has lost 11.8% compared with the industry’s 27.5% decline.
Zacks Rank and Key Picks
PRA Health currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , DexCom (DXCM - Free Report) and Surmodics (SRDX - Free Report) .
ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom’s long-term earnings growth rate is estimated at 36.7%. The company presently carries a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is estimated at 10%. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>